Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial

Florian Eichhorn, Laura V. Klotz, Helge Bischoff, Michael Thomas, Felix Lasitschka, Hauke Winter, Hans Hoffmann, Martin E. Eichhorn
2019 BMC Cancer  
Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed investigating neoadjuvant treatment with anti PD-1 immunotherapy prior to curative intent surgery. Aim of the NEOMUN investigator initiated trial (EudraCT-Number: 2017-000105-20; Identifier: NCT03197467) is to assess feasibility and safety of pre-surgical anti PD-1 treatment in order to improve long term survival.
doi:10.1186/s12885-019-5624-2 fatcat:i6tx6y67jbcundekqwa6tqyxxm